• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Animal & Veterinary

  • Print
  • Share
  • E-mail

WE WANT YOU -- TO REPORT ADVERSE DRUG REACTIONS

FDA Veterinarian Newsletter March/April 1998 Volume XIII, No II

The following is a list of questions and answers related to the importance of reporting adverse drug reactions to the Center for Veterinary Medicine.

What is an ADE?

In common terms, an adverse drug experience (ADE) is either an undesired side effect, or the lack of a desired effect. The Center for Veterinary Medicine (CVM) defines an ADE as "any side effect, injury, toxicity, or sensitivity reaction (or failure to perform as expected) associated with use of an animal drug, whether or not determined to be attributable to the drug."

What are the FDA Center for Veterinary Medicine's specific areas of interest?

The primary purpose of our ADE monitoring system is to detect problems, or "side effects" associated with the use of FDA approved animal drugs. During the research studies that lead to drug approval, only a limited number of animals are treated. Because of this, effects or problems that only occur rarely may not be discovered until after the drug has been more widely marketed and used in a clinical setting.

Lack of effectiveness is an adverse experience. The majority of reports of this nature involve anesthetics, tranquilizers, and anthelmintics. These reports can be difficult to evaluate, but a group of similar reports will prompt further investigation.

CVM gives careful consideration to any reports of adverse experiences occurring in humans as a direct result of using or administering an animal drug or in other situations involving accidental human exposure.

Does CVM review reports that involve extra-label use of animal drugs?

The reporting of ADEs associated with extra-label use is important to the veterinary profession. Under the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA), veterinarians can administer drugs more freely in an extra-label manner. About one-third of the reports on file involve extra-label use. We are also interested in ADEs involving human drugs used in veterinary practice, and in ADEs involving animal drugs marketed without FDA approval.

Who monitors reports of ADEs for products used to treat animals?

The FDA Center for Veterinary Medicine monitors reports of ADEs for animal drug products, medicated feeds, and animal devices under the Federal Food, Drug, and Cosmetic Act.

Animal vaccines and most biologics (e.g., rabies vaccines) are regulated by the United States Department of Agriculture (USDA) under the Federal Virus, Serum and Toxin Act.

Most of the products used topically for the control of ectoparasites and insects on animals are regulated by the Environmental Protection Agency (EPA) under the Federal Insecticide, Fungicide and Rodenticide Act.

The United States Pharmacopeia (USP) operates an independent, non-government reporting program called the Veterinary Practitioner's Reporting Program. USP will forward reports of ADEs to the appropriate regulatory agency and the drug company, at the discretion of the person reporting. This program has the support and endorsement of the American Veterinary Medical Association. The USP program is not affiliated with FDA.

Are there any laws that require reporting of ADEs?

Reporting by veterinary medical professionals is entirely voluntary. However, Federal regulations require that drug companies send FDA all information concerning adverse drug experiences reported to, or coming to the attention of, the company. Products regulated by USDA and EPA do not have the same reporting requirements as animal drugs.

Who submits these reports?

Roughly ninety-five percent of the reports are submitted by drug companies after learning of the adverse experience from a veterinarian or animal owner. The other five percent of reports are submitted directly to CVM by veterinarians and animal owners.

How many reports does CVM receive each year?

Veterinarians at CVM evaluate about two thousand reports annually. This estimate includes reports of product defects.

If I decide to report an ADE, who should I contact?

You should first call the drug company. Inform them that you wish to report an ADE, and ask to speak to a technical services veterinarian. The technical services veterinarian should ask a series of questions about the experience, complete a form called the FDA 1932, and forward the report to CVM. We suggest the drug company as your first point of contact because many companies will also offer clinical advice or diagnostic assistance. CVM does not provide these services. Drug company phone numbers can be obtained from the publications Compendium of Veterinary Products (North American Compendiums Inc.) and Veterinary Pharmaceuticals and Biologics (Veterinary Medicine Publishing Company).

If you wish to confirm that your report was forwarded, or prefer not to call the drug company, you can contact CVM directly at (301) 827-6643 or toll-free at (888) FDA-VETS. Please ask to speak to one of the veterinarians responsible for the ADE monitoring program. We can also provide a supply of prepaid mailers (Form FDA 1932a). These mailers are available by writing or telephoning CVM and are also distributed at veterinary medicine meetings and seminars.

If the ADE involves a product other than a drug, the following numbers may be useful. The phone number to reach USDA regarding biologics is (800) 752-6255. The phone number to reach EPA regarding topical insecticides is (800) 858-7378. A third option for reporting is the Veterinary Practitioners' Reporting Network (USP PRN) sponsored by the United States Pharmacopeia. The USP PRN program is an independent, non-government reporting program. The phone number to reach USP regarding any veterinary product is (800) 4-USPPRN.

What happens after I report an ADE?

Each ADE report is evaluated by a veterinarian and entered in a computer database. The reviewer assigns codes to items that describe the drug(s) and animal(s) involved. These items become separate fields of information. The reviewer also enters a brief clinical description of the ADE, and makes an assessment of whether the event is judged to be drug-related using an algorithm scoring system.

CVM publishes an annual summary of ADE reports. The summary provides the number of reports and the clinical signs associated with each drug in the database. The information is limited to those reports that were assessed as at least "possibly drug-related." The publication is available from the FDA Center for Veterinary Medicine.

Other information and reports from the database can be requested on an individual basis by filing a written Freedom of Information (FOI) request. For more information about filing a request, contact the CVM Communications Staff at (301) 594-1755.

What actions result from reports of ADEs?

A group of similar reports submitted in a short period of time may alert CVM and the drug company to a problem with a particular lot of drug. This may result in a product recall of the affected lot.

Another outcome would be for a label change to include new information gleaned from reported ADEs. The changes may include new warnings, contraindications or human safety information. In very rare instances, a drug may be removed from the market due to problems discovered by ADE reporting.

At times, CVM may require the involved drug company to issue a "Dear Doctor" letter to veterinarians informing them of the type of actions that had resulted from ADE reports.

Why should veterinarians in practice care about reporting an ADE?

Veterinarians in practice depend on the information available in drug labeling to make informed choices about the risk and benefits associated with the use of a drug. The purpose of ADE monitoring is to ensure that animal drug labeling is adequate and accurate.

In spite of the highest standards for safety and effectiveness that exist for FDA approval, not everything is known about a drug when it is first marketed. Due to the limited size and controlled nature of premarketing clinical trials, only the most common adverse events will be observed and included in product labeling at the time of FDA approval. An accurate safety profile emerges only after a product is marketed and the number and spectrum of animals receiving the drug increases.

As a practicing veterinarian, you are in a unique position to observe adverse clinical outcomes associated with the use of drug products. Some of these problems may only be associated with extra-label drug use. You can assist in the development of a complete safety profile by reporting adverse experiences. Such reports are often the first signal that a problem exists. By participating in the reporting program and contributing to our knowledge of animal drugs, you provide a valuable service to animals, the public, and your colleagues in the veterinary profession.

Where can I obtain information for a specific drug concerning potential adverse reactions?

The drug manufacturer is usually the best source for this type of information. Other sources include the FDA Center for Veterinary Medicine, the FDA/CVM Internet World Wide Web server (http://www.cvm.fda.gov/), the National Animal Poison Control Center and veterinary computer networks, such as VIN (America Online) and NOAH (Compuserve).